The Impact of Biologics on the Treatment of CRSwNP: Targeting Type 2 Inflammation


Joseph K. Han, MD, FARS, FAAAAI
Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery
Chief, Division of Allergy Eastern Virginia Medical School Norfolk, VA ARS, Immediate Past President AAAAI, RROAC, Chair
Joseph K. Han, MD, FARS, FAAAAI

Dr. Joseph Han is a Professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School. He is the Chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the Chief for the Division of Allergy. Previously, Dr. Han was the Director for the Division of Rhinology and Endoscopic Sinus Surgery at University of Virginia School of Medicine. Dr. Joseph Han is currently the Immediate Past President for the American Rhinologic Society. He was the President for the Virginia Society of Otolaryngology, President of the Tidewater Otolaryngology & Ophthalmology Society, President of the Korean American Otolaryngology Society, and Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. He is the Chair for the Rhinitis, Rhinosinusitis, and Ocular Allergy Committee within the American Academy of Allergy, Asthma, and Immunology.

Dr. Han was an Associate Editor and is on the Editorial Board for the International Forum of Allergy and Rhinology. Dr. Han is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. Dr. Han is the Editor for the book Practical Medical and Surgical Management of Chronic Rhinosinusitis and Rhinology Section Editor for the Ballenger’s Otolaryngology Head and Neck Surgery. He has over 118 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Dr. Han is a fellow of the American Academy of Otolaryngology & Head and Neck Surgery (AAO-HNS), American Rhinologic Society (ARS), Triological Society, American Academy of Allergy, Asthma, and Immunology (AAAAI), American College of Surgeons (ACS), and American Academy of Otolaryngic Allergy (AAOA). He was involved in the Guideline Task Force. Dr. Han is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA. Dr. Han has received numerous awards including Best Doctors of America and Top Doctors by US News & Report.

Dr. Han is very active in both basic science research as well as clinical research studies. His thesis was on subclassification of CRS, which is endotyping and phenotyping CRS. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigators for several multi-national, multi- institutional, prospective clinical trials on chronic sinusitis and nasal polyposis.

Stella Lee, MD
Section Chief, Rhinology
Division of Otolaryngology-Head & Neck Surgery
Brigham and Women's Hospital Harvard Medical School Boston, MA
Stella Lee, MD

Dr. Stella Lee is a fellowship-trained rhinologist and director of the Brigham Sinus Center. She is a clinician scientist developing novel management strategies for the care of patients with inflammatory upper airway disease as well as a leader in the development of therapeutics for airway inflammation. Her philosophy is to provide multi-disciplinary care with experts in the field for the best outcome possible for her patients.

Dr. Lee earned her Bachelor of Science degree in Neuroscience from Duke University before attending the Chicago Medical School. She completed her residency in Otolaryngology-Head and Neck Surgery at Yale University, followed by a fellowship in Rhinology and Skull Base Surgery at Johns Hopkins University. Before joining the Brigham faculty, Dr. Lee served as the Division Chief for Sinonasal Disorders and Allergy in the Department of Otolaryngology at the University of Pittsburgh Medical Center for ten years.

Her research interests include understanding the inflammatory endotypes of chronic rhinosinusitis, the impact of environmental pollution on airway inflammation, and development of basic to translational approaches to solve chronic inflammation ( She is a leader in the investigation of targeted therapeutics and creation of new paradigms of how we conceptualize and treat upper airway disorders.

Statement of Need

The pathophysiology of chronic rhinosinusitis with nasal polyposis (CRSwNP) is complex, including the pathways of type 2 inflammation. As understanding of the underlying pathophysiology of CRSwNP expands, so does the potential list of targeted biologic therapies that may produce superior outcomes and safety compared to standard therapy. Determining how these agents are best utilized in CRSwNP requires additional research, and until then, many questions remain. Currently, there remains a lack of consensus on the correct timing of these medications, and clinicians require education on contemporary research regarding the use of biologics in CRSwNP.

Please join Dr. Han and Dr. Lee in part 3 of a CMEO Snack series on CRSwNP, as they discuss the pathophysiology of CRSwNP and safety and efficacy data for biologics targeting type 2 inflammation and individualizing treatment.


Learning Objectives

At the end of this CME/CE activity, participants should be able to apply efficacy and safety data to treatment decisions for patients with CRSwNP.

Financial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-21-062-H02-P

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Through a mutual recognition agreement between the AMA and the UEMS-EACCME®, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to mitigate conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. [Hard return + divider]

Dr. Han reports the following financial relationships: Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme

Dr. Lee reports the following financial relationships: Consultant and Research Support: AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Sanofi Regeneron.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report

  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Janan Sarwar, PharmD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


The Impact of Biologics on the Treatment of CRSwNP: Targeting Type 2 Inflammation
Event Date: 05/22/2022